Table 1 Baseline patient characteristics.

From: Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial

 

Dose level 25 mg (N = 15)

Dose level 37.5 mg (N = 3)

Total (N = 18)

Median age (years; range)

73.7 (63–84)

71.7 (57–84)

73.3 (57–84)

Histology

 Ductal

12 (80%)

3 (100%)

15 (83%)

 Lobular

3 (20%)

0

3 (17%)

Histological grade

 G1

1 (7%)

0

1 (5%)

 G2

4 (27%)

1 (33%)

5 (28%)

 Not reported

10 (67%)

2 (67%)

12 (67%)

Ki67 index

 ≤ 20%

11 (73%)

3 (100%)

14 (78%)

 > 20%

4 (27%)

0

4 (22%)

Tumor size (T)

 T2

11 (73%)

3 (100%)

14 (78%)

 T3

2 (13%)

0

2 (11%)

 T4

2 (13%)

0

2 (11%)

Nodal involvement (N)

 N0/N1mi

5 (33%)

2 (67%)

7 (38%)

 N1

8 (53%)

1 (33%)

9 (50%)

 N2

1 (7%)

0

1 (6%)

 N3

1 (7%)

0

1 (6%)

Back to article page